Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal

Cell Reports

Volumn 8, Issue 6, 2014, Pages 1974-1988

  Ptasinska, Anetta ^a   Assi, Salam A ^a,c   Martinez Soria, Natalia ^d   Imperato, Maria Rosaria ^a   Piper, Jason ^b   Cauchy, Pierre ^a   Pickin, Anna ^a   James, Sally R ^f   Hoogenkamp, Maarten ^a   Williamson, Dan ^d   Wu, Mengchu ^e   Tenen, Daniel G ^e   Ott, Sascha ^b   Westhead, David R ^c   Cockerill, Peter N ^a   Heidenreich, Olaf ^d   Bonifer, Constanze ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; HISTONE DEACETYLASE; HYBRID PROTEIN; RNA; TRANSCRIPTION FACTOR RUNX1; CCAAT ENHANCER BINDING PROTEIN ALPHA; LIM PROTEIN; LMO2 PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN SPI-1; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING SITE; BLOOD CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; RNA SEQUENCE; TRANSCRIPTION INITIATION; ACUTE MYELOBLASTIC LEUKEMIA; CHROMOSOME 21; CHROMOSOME 8; CHROMOSOME MAP; GENE REGULATORY NETWORK; GENE TRANSLOCATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIM DOMAIN PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84907412586     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.024     Document Type: Article

References (55)

1. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., Hiebert S.W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 2001, 21:6470-6483.
2. Ben-Ami O., Friedman D., Leshkowitz D., Goldenberg D., Orlovsky K., Pencovich N., Lotem J., Tanay A., Groner Y. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep 2013, 4:1131-1143.
3. Chimge N.O., Frenkel B. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 2013, 32:2121-2130.
4. Davidson E.H. Emerging properties of animal gene regulatory networks. Nature 2010, 468:911-920.
5. DeVilbiss A.W., Sanalkumar R., Johnson K.D., Keles S., Bresnick E.H. Hematopoietic transcriptional mechanisms: From locus-specific to genome-wide vantage points. Exp. Hematol. 2014, 42:618-629.
6. Diffner E., Beck D., Gudgin E., Thoms J.A., Knezevic K., Pridans C., Foster S., Goode D., Lim W.K., Boelen L., et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood 2013, 121:2289-2300.
7. Dunne J., Cullmann C., Ritter M., Soria N.M., Drescher B., Debernardi S., Skoulakis S., Hartmann O., Krause M., Krauter J., et al. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene 2006, 25:6067-6078.
8. Follows G.A., Tagoh H., Lefevre P., Hodge D., Morgan G.J., Bonifer C. Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J. 2003, 22:2798-2809.
9. Gaidzik V.I., Bullinger L., Schlenk R.F., Zimmermann A.S., Röck J., Paschka P., Corbacioglu A., Krauter J., Schlegelberger B., Ganser A., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J.Clin. Oncol. 2011, 29:1364-1372.
10. Goyama S., Schibler J., Cunningham L., Zhang Y., Rao Y., Nishimoto N., Nakagawa M., Olsson A., Wunderlich M., Link K.A., et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J.Clin. Invest. 2013, 123:3876-3888.
11. Heidenreich O., Krauter J., Riehle H., Hadwiger P., John M., Heil G., Vornlocher H.P., Nordheim A. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003, 101:3157-3163.
12. Heinz S., Benner C., Spann N., Bertolino E., Lin Y.C., Laslo P., Cheng J.X., Murre C., Singh H., Glass C.K. Simple combinations of lineage-determining transcription factors primecis-regulatory elements required for macrophage and B cell identities. Mol. Cell 2010, 38:576-589.
13. Kitabayashi I., Yokoyama A., Shimizu K., Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998, 17:2994-3004.
14. Leddin M., Perrod C., Hoogenkamp M., Ghani S., Assi S., Heinz S., Wilson N.K., Follows G., Schönheit J., Vockentanz L., et al. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 2011, 117:2827-2838.
15. Lefevre P., Melnik S., Wilson N., Riggs A.D., Bonifer C. Developmentally regulated recruitment of transcription factors and chromatin modification activities to chicken lysozymecis-regulatory elements invivo. Mol. Cell. Biol. 2003, 23:4386-4400.
16. Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D., Stifani S., Paroush Z., Groner Y. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 1998, 95:11590-11595.
17. Lichtinger M., Ingram R., Hannah R., Müller D., Clarke D., Assi S.A., Lie-A-Ling M., Noailles L., Vijayabaskar M.S., Wu M., et al. RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis. EMBO J. 2012, 31:4318-4333.
18. Liu Y., Cheney M.D., Gaudet J.J., Chruszcz M., Lukasik S.M., Sugiyama D., Lary J., Cole J., Dauter Z., Minor W., et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 2006, 9:249-260.
19. Mandoli A., Singh A.A., Jansen P.W., Wierenga A.T., Riahi H., Franci G., Prange K., Saeed S., Vellenga E., Vermeulen M., et al. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. Leukemia 2014, 28:770-778.
20. Martens J.H., Mandoli A., Simmer F., Wierenga B.J., Saeed S., Singh A.A., Altucci L., Vellenga E., Stunnenberg H.G. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 2012, 120:4038-4048.
21. Martinez N., Drescher B., Riehle H., Cullmann C., Vornlocher H.P., Ganser A., Heil G., Nordheim A., Krauter J., Heidenreich O. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer 2004, 4:44.
22. Martinez Soria N., Tussiwand R., Ziegler P., Manz M.G., Heidenreich O. Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation invivo. Leukemia 2009, 23:188-190.
23. McNeil S., Zeng C., Harrington K.S., Hiebert S., Lian J.B., Stein J.L., van Wijnen A.J., Stein G.S. The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor. Proc. Natl. Acad. Sci. USA 1999, 96:14882-14887.
24. Michaud J., Wu F., Osato M., Cottles G.M., Yanagida M., Asou N., Shigesada K., Ito Y., Benson K.F., Raskind W.H., et al. Invitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
25. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993, 12:2715-2721.
26. Natoli G., Ghisletti S., Barozzi I. The genomic landscapes of inflammation. Genes Dev. 2011, 25:101-106.
27. Pabst T., Mueller B.U., Harakawa N., Schoch C., Haferlach T., Behre G., Hiddemann W., Zhang D.E., Tenen D.G. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 2001, 7:444-451.
28. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Hiddemann W., Tenen D.G. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet. 2001, 27:263-270.
29. Pimanda J.E., Göttgens B. Gene regulatory networks governing haematopoietic stem cell development and identity. Int. J. Dev. Biol. 2010, 54:1201-1211.
30. Piper J., Elze M.C., Cauchy P., Cockerill P.N., Bonifer C., Ott S. Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res. 2013, 41:e201.
31. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., Thomas X., Raffoux E., Lamandin C., Castaigne S., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723. ALFA Group.
32. Ptasinska A., Assi S.A., Mannari D., James S.R., Williamson D., Dunne J., Hoogenkamp M., Wu M., Care M., McNeill H., et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012, 26:1829-1841.
33. Reed-Inderbitzin E., Moreno-Miralles I., Vanden-Eynden S.K., Xie J., Lutterbach B., Durst-Goodwin K.L., Luce K.S., Irvin B.J., Cleary M.L., Brandt S.J., Hiebert S.W. RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene 2006, 25:5777-5786.
34. Saeed S., Logie C., Francoijs K.J., Frigè G., Romanenghi M., Nielsen F.G., Raats L., Shahhoseini M., Huynen M., Altucci L., et al. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012, 120:3058-3068.
35. Scheitz C.J., Tumbar T. New insights into the role of Runx1 in epithelial stem cell biology and pathology. J.Cell. Biochem. 2013, 114:985-993.
36. Scheitz C.J., Lee T.S., McDermitt D.J., Tumbar T. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J. 2012, 31:4124-4139.
37. Schwieger M., Schüler A., Forster M., Engelmann A., Arnold M.A., Delwel R., Valk P.J., Löhler J., Slany R.K., Olson E.N., Stocking C. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 2009, 114:2476-2488.
38. Scott E.W., Simon M.C., Anastasi J., Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994, 265:1573-1577.
39. Snaddon J., Smith M.L., Neat M., Cambal-Parrales M., Dixon-McIver A., Arch R., Amess J.A., Rohatiner A.Z., Lister T.A., Fitzgibbon J. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003, 37:72-78.
40. Staber P.B., Zhang P., Ye M., Welner R.S., Nombela-Arrieta C., Bach C., Kerenyi M., Bartholdy B.A., Zhang H., Alberich-Jordà M., et al. Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol. Cell 2013, 49:934-946.
41. Stender J.D., Kim K., Charn T.H., Komm B., Chang K.C., Kraus W.L., Benner C., Glass C.K., Katzenellenbogen B.S. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 2010, 30:3943-3955.
42. Sun X.J., Wang Z., Wang L., Jiang Y., Kost N., Soong T.D., Chen W.Y., Tang Z., Nakadai T., Elemento O., et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 2013, 500:93-97.
43. Taniuchi I., Osato M., Egawa T., Sunshine M.J., Bae S.C., Komori T., Ito Y., Littman D.R. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002, 111:621-633.
44. Taoudi S., Bee T., Hilton A., Knezevic K., Scott J., Willson T.A., Collin C., Thomas T., Voss A.K., Kile B.T., et al. ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev. 2011, 25:251-262.
45. Tijssen M.R., Cvejic A., Joshi A., Hannah R.L., Ferreira R., Forrai A., Bellissimo D.C., Oram S.H., Smethurst P.A., Wilson N.K., et al. Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev. Cell 2011, 20:597-609.
46. Tsuzuki S., Seto M. Expansion of functionally defined mouse hematopoietic stem and progenitor cells by a short isoform of RUNX1/AML1. Blood 2012, 119:727-735.
47. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Löwenberg B., Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N.Engl. J. Med. 2004, 350:1617-1628.
48. van Riel B., Pakozdi T., Brouwer R., Monteiro R., Tuladhar K., Franke V., Bryne J.C., Jorna R., Rijkers E.J., van Ijcken W., et al. A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells. Mol. Cell. Biol. 2012, 32:3814-3822.
49. Vangala R.K., Heiss-Neumann M.S., Rangatia J.S., Singh S.M., Schoch C., Tenen D.G., Hiddemann W., Behre G. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2003, 101:270-277.
50. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA 1998, 95:10860-10865.
51. Wang L., Gural A., Sun X.J., Zhao X., Perna F., Huang G., Hatlen M.A., Vu L., Liu F., Xu H., et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011, 333:765-769.
52. Wilson N.K., Foster S.D., Wang X., Knezevic K., Schütte J., Kaimakis P., Chilarska P.M., Kinston S., Ouwehand W.H., Dzierzak E., et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 2010, 7:532-544.
53. Zhang D.E., Zhang P., Wang N.D., Hetherington C.J., Darlington G.J., Tenen D.G. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 1997, 94:569-574.
54. Zhang P., Iwasaki-Arai J., Iwasaki H., Fenyus M.L., Dayaram T., Owens B.M., Shigematsu H., Levantini E., Huettner C.S., Lekstrom-Himes J.A., et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004, 21:853-863.
55. Zhang H., Alberich-Jorda M., Amabile G., Yang H., Staber P.B., Di Ruscio A., Welner R.S., Ebralidze A., Zhang J., Levantini E., et al. Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell 2013, 11:575-588.